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Abstract
Background: Adverse events (AEs) among HIV-infected patients with multidrug-resistant tuberculosis (MDR-TB)
receiving anti-TB and antiretroviral treatments (ART) are under-researched and underreported. Hypothyroidism is a
common AE associated with ethionamide, p-aminosalicylic acid (PAS), and stavudine. The aim of this study was to
determine the frequency of and risk factors associated with hypothyroidism in HIV/MDR-TB co-infected patients.
Methods: This was a prospective, observational cohort study, using routine laboratory data in a Médecins Sans
Frontières (MSF) clinic in collaboration with Sewri TB Hospital, Mumbai, India. Hypothyroidism was defined as a
thyroid stimulating hormone (TSH) result >10 mIU/L at least once during treatment. Patients having a baseline result
and one additional result after 3 months were eligible for enrolment.
Results: Between October 2006 and March 2013, 116 patients were enrolled, 69 of whom were included. The
median (IQR) age was 38 years (34-43) and 61% were male. By March 2013, 37/69 (54%) had hypothyroidism after
at least 90 days of treatment. Age, gender, CD4 counts and stavudine-based ART were not associated with the
occurrence of hypothyroidism in multivariate models. The co-administration of PAS and ethionamide was found to
double the risk of hypothyroidism (RR: 1.93, 95% CI: 1.06-3.54).
Discussion: High rate of hypothyroidism was recorded in a Mumbai cohort of MDR-TB/HIV co-infected patients on
treatment. This is a treatable and reversible AE, however, it may go undiagnosed in the absence of regular
monitoring. Care providers should not wait for clinical symptoms, as this risks compromising treatment adherence.
Simple, affordable and reliable point-of-care tools for measuring TSH are needed, especially in high MDR-TB burden
countries. Our findings suggest the need for TSH screening at baseline, three months, six months, and every six
months thereafter for HIV-infected patients on MDR-TB treatment regimens containing PAS and/or ethionamide, until
newer, safer and more efficacious MDR-TB regimens become available.
Citation: Andries A, Isaakidis P, Das M, Khan S, Paryani R, et al. (2013) High Rate of Hypothyroidism in Multidrug-Resistant Tuberculosis Patients Co-
Infected with HIV in Mumbai, India. PLoS ONE 8(10): e78313. doi:10.1371/journal.pone.0078313
Editor: Massimo Pietropaolo, University of Michigan Medical School, United States of America
Received May 31, 2013; Accepted September 10, 2013; Published October 23, 2013
Copyright: © 2013 Andries et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: msfocb-asia-epidemio@brussels.msf.org
Introduction
The number of people being initiated on treatment for
multidrug-resistant tuberculosis (MDR-TB) almost doubled
between 2009 and 2011 as a result of steady annual increases
in 12 of 27 countries having a high MDR-TB burden. This
includes India where 3384 cases were enrolled on MDR-TB
treatment in 2011 compared to 1136 in 2009. Improved
capacity for MDR-TB case detection has also contributed to the
increasing number of cases[1]. The increasing trend towards
drug-resistant TB in several high burden countries throughout
the world will pose a serious public health threat for future
generations[1-3].
MDR-TB is defined as tuberculosis that is resistant to
isoniazid and rifampicin, the two most effective anti-TB drugs in
the first-line regimen[2,4]. Treatment for patients having MDR
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strains requires use of second-line anti-TB drugs and a
treatment duration of at least 20 months[2,4-6]. An MDR-TB
regimen is best chosen based on drug susceptibility testing
(DST) results and assessment of the past treatment history,
and typically consists of a minimum of 5 drugs, of which 4 are
second-line anti-TB drugs: any first-line drugs thought to be
effective, one injectable agent, one fluoroquinolone, and more
than one of the oral bacteriostatic second-line anti-TB drugs
(cycloserine/terizidone, ethionamide/prothionamide, +/- p-
aminosalicylic acid or PAS)[6,7]. In cases having more
advanced resistance, such as extensively drug-resistant TB
(XDR-TB), all oral bacteriostatic second-line anti-TB drugs may
need to be used[8,9], as well as some ‘group 5’ drugs having
unclear efficacy (clofazimine, linezolid, etc)[5,10,11].
Second-line anti-TB drugs are more likely to cause adverse
events (AE) than the first-line anti-tuberculosis drugs used in
drug-sensitive TB treatment[2,12,13]. One of the known AEs
related to MDR-TB treatment is hypothyroidism. The second-
line anti-TB drugs associated with hypothyroidism include
ethionamide, prothionamide, and PAS[2,4,14]. These drugs
can cause hypothyroidism by inhibiting thyroid hormone
synthesis through a mechanism of iodine organification
inhibition[15,16]. Clinical hypothyroidism presents with the
following symptoms and signs: slowing in both mental and
physical activities, dry skin, cold sensitivity, fatigue, muscle
cramps, voice changes, and constipation[17]. In rare cases,
hypothyroidism can manifest severely as cardiac disease and
development of a pericardial effusion[18].
MDR-TB treatment in patients co-infected with HIV remains a
challenge. Patients are required to take a large number of
medicines for treating both diseases and additionally, for
managing AEs. Antiretrovirals and drug-resistant TB drugs
have potentially overlapping AEs[14,19,20]. In a multivariate
analysis of a study of HIV patients receiving ART, cumulative
dosing of stavudine was associated with subclinical
hypothyroidism[21]. Efavirenz, amprenavir, lopinavir, and
ritonavir were also found to be associated with
hypothyroidism[22]. A number of studies looking at
hypothyroidism in MDR-TB cohorts not co-infected with HIV
and mixed cohorts of HIV/MDR-TB co-infected and non-HIV
co-infected patients have identified ethionamide and PAS as
the most likely culprit drugs[23-26]. However, there are limited
data on hypothyroidism in MDR-TB patients co-infected with
HIV.
The aim of this study was to determine the frequency of and
risk factors associated with hypothyroidism in a cohort of MDR-
TB patients co-infected with HIV in Mumbai, India.
Methods
Study design
The study was a prospective, observational cohort study
using routine clinical and laboratory data.
Setting and study population
Médecins Sans Frontières (MSF) started an HIV project in
Mumbai, India in 2006, into which treatment for both drug-
sensitive and drug-resistant TB were integrated. HIV-infected
patients initiated on a multidrug-resistant TB regimen between
October 2006 and March 2013 were eligible for enrolment in
this study.
Treatment protocol and follow-up
All patients received therapy for drug-resistant TB (DR-TB)
using a model of care that involves ambulatory, community-
based, directly observed treatment (DOT) as previously
described elsewhere[19]. An individualized treatment regimen
was designed for each patient based on first- and second-line
DST results and the patient’s previous TB treatment history.
Any patient who required immediate treatment was initiated on
an empiric treatment regimen consisting of pyrazinamide,
capreomycin, moxifloxacin, ethionamide, cycloserine, and PAS
while awaiting the DST result; treatment was then either
individualized once DST results became available, or the
empiric regimen continued for culture-negative patients with a
strong suspicion of drug-resistant TB based on TB treatment
history. Some patients initially enrolled in the program were
treated for a duration of 18 months following the WHO
guidelines at that time[4]. Once the WHO guidelines were
updated in 2011, the treatment duration was adjusted
accordingly to a minimum of 20 months[6]. Patients underwent
monthly follow-up in the MSF clinic and thyroid-stimulating
hormone (TSH) levels were tested every 3 months. When
patients required hospitalization, MSF collaborated with private
and government hospitals; Sewri TB Hospital was the only
government hospital in Mumbai having hospital wards
designed to accommodate tuberculosis patients.
Patients diagnosed with TB were eligible for antiretroviral
therapy (ART) irrespective of the CD4 count. Thus, all patients
not already on ART when they enrolled in the MSF clinic
received ART as soon as they tolerated second-line TB
treatment. Patients received two nucleoside/tide reverse
transcriptase inhibitors (NRTIs) and one non-nucleoside
reverse transcriptase inhibitor (NNRTI) in their first-line ART
regimen. Protease inhibitor-based regimens were used for
patients in need of second-line and third-line ART.
TSH was measured using the serum chemiluminescence
method in a private laboratory (RLS, Religare, Mumbai, India)
accredited by the College of American Pathologists. The
reference range of laboratory detection for TSH was 0.35-5.5
mIU/L.
Data collection and statistical analysis
Data related to HIV/MDR-TB co-infected patients initiated on
treatment between October 2006 and March 2013 were
included in the analysis. Data were routinely collected during
each consultation and entered into handwritten patient files and
an electronic database. Both HIV and TB data were collected
from integrated patient file systems.
Hypothyroidism can be differentiated into subclinical (defined
as elevated serum TSH above the upper limit in combination
with normal free thyroxine (T4)) versus overt hypothyroidism
(elevated TSH, usually above 10 mIU/L, in combination with
low T4)[17]. In this study, hypothyroidism was defined as at
least one TSH value > 10 mIU/L after at least 3 months of
second line TB treatment.
Hypothyroidism in HIV/MDR-TB Co-Infected Patients
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Patient characteristics were summarized using descriptive
statistics. We used t-test, chi-square or Fisher’s exact test to
assess differences of variables between groups, as
appropriate. The time-to-hypothyroidism was measured using
Kaplan-Meier analysis (data were censored by 30th March
2013). We performed bi- and multi-variate analyses to assess
risk factors associated with the occurrence of hypothyroidism.
We calculated Relative Risks and adjusted Hazard Ratios (with
95% Confidence Intervals) using bivariate and Cox regression
models respectively. Factors used as predictors included age,
sex, baseline CD4 count, baseline body mass index (BMI),
tuberculosis site (pulmonary vs. extrapulmonary), and TB
treatment regimen. We used the cohort’s median age as a cut-
off point in the modeling. When patients had both pulmonary
and extrapulmonary TB, we classified them as extrapulmonary
TB for the modeling. A p-value of less than 0.05 was
considered to indicate statistical significance. SPSS (IBM,
SPSS, Statistics, version 20) was used for analysis.
Ethics
The study satisfied the criteria for reports using routinely
collected programmatic data, set by the Médecins Sans
Frontières independent Ethics Review Board (MSF ERB) in
Geneva, Switzerland. Informed consent to the patient was not
obtained since the data used in the study were routinely
collected for treatment monitoring. The MSF ERB specifically
approved the study and waived the need for consent.
Results
Between October 2006 and March 2013, 116 drug-resistant
TB patients co-infected with HIV were enrolled in the MSF
clinic, of whom ninety-six (82.8%) had a baseline TSH value
measured. Twenty-three of these (24.0%) did not fulfill the
study definition and were excluded from the analysis; 18
patients have no follow up TSH measurement after 3 months, 1
patient lost to follow up, and 4 patients died before TSH follow
up. Another four patients (4.2%) had an elevated TSH at
baseline and were also not included. Thus, a total of sixty-nine
patients met the study criteria and were included in the
analysis, as shown in Figure 1. Clinical characteristics of these
patients are presented in Table 1.
Out of 69 patients analyzed as of March 2013, 37 (53.6%)
developed hypothyroidism during the study period (Figure 1).
Twenty-three of them (62%) were diagnosed with
hypothyroidism at 90 days (i.e. the first TSH follow up), while
12 more patients were diagnosed at 180 days. The remaining
two patients were diagnosed at 240 and 300 days respectively.
Figure 2 shows the Kaplan-Meier curve of time-to-
hypothyroidism after MDR-TB treatment initiation.
In 67 out of 69 patients included in the analysis, ethionamide
and/or PAS were included in the regimen. Forty-five (67%)
patients received both ethionamide and PAS, while the
remaining 22 patients received either ethionamide or PAS.
There was no difference in the time-to-hypothyroidism between
the patients who received both drugs and the ones who
received just one of the two. There was a significant
association between the use of both ethionamide and PAS in
the regimen and developing hypothyroidism (p = 0.014) as
presented in Table 1. Co-administration of these two agents
increased the risk of hypothyroidism by two-fold (relative risk:
1.93, 95% CIs: 1.06-3.54). Age, sex, category of TB
(pulmonary or extra-pulmonary) and stavudine were not
associated with the occurrence of hypothyroidism. No factors
were found to be associated with the occurrence of
hypothyroidism in multivariate models (Table 2).
Discussion
Hypothyroidism was recorded in the majority (53.6%) of this
Mumbai cohort of HIV/MDR-TB co-infected patients on both
antiretroviral and second-line TB treament. In a previous
analysis of data from this cohort we have found lower rate of
hypothyroidism (32%)[14]. We assume that the increased rate
is due to longer exposure of the cohort to 2nd line drugs and a
greater proportion of patients receiving both PAS and
ethionamide. All 37 patients in whom hypothyroidism was
detected were asymptomatic. An MSF clinic protocol assured
that the patients who have elevated TSH > 10 mIU/L, whether
symptomatic or not, would receive levothyroxine 50-150 μg
daily based on the patient’s weight and titrated according to the
response to therapy. This approach prevents the emergence of
symptomatic hypothyroidism in patients attending the MSF
clinic.
Although stavudine has been found elsewhere to be
associated with the occurrence of hypothyroidism[21], no
association was found in this study. It should be noted that
stavudine is no longer preferred in a first-line ART regimen[27];
only 15/69 (21.7%) patients were still on a stavudine-based
ART regimen during the study period, of which seven patients
developed hypothyroidism. Similarly sex was previously found
to be associated with hypothyroidism in HIV-infected patients
but we found no such association in our Mumbai cohort of co-
infected patients on treatment[21].
In our study, lower CD4 cell counts were associated with
hypothyroidism in bivariate analysis, which may be a result of
HIV infection itself being associated with thyroid dysfunction.
Patients with low CD4 cell counts may be at higher risk of
opportunistic infections that could affect the thyroid, such as
hypothyroidism due to infiltration of Kaposi’s Sarcoma cells into
the thyroid gland[28]. According to the literature, thyroid
dysfunction may have infectious, hemorrhagic, or neoplastic
etiologies[29-31].
The mechanism of hypothyroidism due to second-line anti-
TB drugs is clear and it is both treatable and reversible (upon
discontinuation of the offending drug)[15,16]. Even mild or
subclinical hypothyroidism should not be overlooked as it may
increase the risk of co-morbidities such as depression[32]. In
addition to a potential negative effect on adherence to MDR-TB
treatment, untreated depression will also result in suboptimal
adherence to antiretroviral treatment[33]. In our setting, we
managed to prevent overt hypothyroidism by detecting it early
and treating it promptly.
A high rate of hypothyroidism (69%) was also found in a DR-
TB cohort from Lesotho having an HIV co-infection rate of
almost 70%[24]. However, findings have varied in other
Hypothyroidism in HIV/MDR-TB Co-Infected Patients
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studies: a study of MDR-TB adverse events in Tomsk, Russia
reported a 17.2% incidence of hypothyroidism[34], while five
out of seven patients (71.4%) treated for MDR-TB with both
PAS and prothionamide in the United Kingdom also developed
hypothyroidism. Though the number of patients in the latter
study was small, it was the largest cohort of patients
developing drug-induced hypothyroidism in the United
Kingdom[23]. Co-infection with HIV was not discussed in either
of these studies. Another study conducted in KwaZulu-Natal
province in South Africa looking for adverse events in an MDR-
TB program reported hypothyroidism in 36%, the most
common adverse event among the cohort. Most of the patients
enrolled in this study (81%) were HIV-positive and receiving
ART. [35]
In Sewri TB hospital, where the largest cohort of MDR-TB
patients is being treated in Mumbai, unpublished data related
to 115 patients on MDR-TB treatment between the years 2005
and 2010 showed only six patients (5%) had hypothyroidism.
However, these six patients had TSH laboratory testing only
when they were symptomatic, as recommended in the Indian
national guidelines[36]; three of the patients had thyroid
swelling and the other three had symptoms of hypothyroidism.
Since TSH was not systematically tested in all the MDR-TB
patients and had to be paid for by patients, the true rate of
hypothyroidism is likely to be very much underestimated.
Despite being one of the largest cohorts of HIV/MDR-TB
patients in India, the relatively small number of patients in this
report is one of the study limitations. On the other hand, these
operational data reflect the reality of patient care in our setting,
which has room for improvement. Of the 47 patients excluded
from the study (Figure 1), 18 of them did not have two TSH
measurements (i.e. at baseline and 3 months after TB
treatment started), 1 patient was lost to follow up, 4 patients
died before TSH follow up, 4 patients have elevated TSH at
Figure 1.  HIV/MDR-TB co-infected patients who developed hypothyroidism during the study period.  
doi: 10.1371/journal.pone.0078313.g001
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baseline, and 20 of the patients did not have a baseline TSH
result. The study also did not measure the prevalence of iodine
deficiency, although it should be noted that India is among
those countries where iodine intake tends to be adequate[37].
In India and elsewhere, ethionamide is included in the
national standardized MDR-TB regimen. PAS is also used if
other second-line agents such as ethionamide and/or
cycloserine cannot be used. The high rate of hypothyroidism
Table 1. Bi-variate analysis for development of hypothyroidism during treatment among HIV/MDR-TB co-infected patients,
Mumbai, India, 2013.
Explanatory Variable Total (n=69) n (%)   
Patients developed hypothyroidism n
(%)   
Patients did not develop hypothyroidism n
(%)   p-value   RR (95% CI)
Age (years, mean ± SD) 37.38 ± 9.61 38.84 ± 9.11 35.69 ± 10.04 0.176 -
Sex of patients      
Male 42 (60.9) 22 (59.5) 20 (62.5) 0.796 0.94 (0.60-1.47)
Female 27 (39.1) 15 (40.5) 12 (37.5)   
Category of TB      
Pulmonary 41 (59.4) 21 (56.8) 20 (62.5) 0.628 0.90 (0.58-1.39)
Extra-pulmonary 28 (40.6) 16 (43.2) 12 (37.5)   
Baseline CD4 count      
Less than 200 49 (71.0) 30 (81.1) 19 (59.4) 0.047* 1.75 (0.92-3.31)
200 and above 20 (29.0) 7 (18.9) 13 (40.6)   
ART regimen      
Stavudine 15 (21.7) 7 (18.9) 8 (25.0) 0.541 0.84 (0.46-1.52)
No stavudine 54 (78.3) 30 (81.1) 24 (75.0)   
Medication on treatment      
Eto and PAS 24 (34.8) 8 (21.6) 16 (50.0) 0.014* 1.93 (1.06-3.54)
Other than Eto/PAS combination 45 (65.2) 29 (78.4) 16 (50.0)   
Baseline BMI (mean ± SD) 17.37 ± 4.05 17.83 ± 4.09 16.83 ± 4.00 0.310 -
Total number of patients (N) 69 37 32  69
Eto: Ethionamide, PAS: Para-Aminosalicylic acid, RR: Relative Risk, CI: Confidence Intervals
*. Levels of significance are p < 0.05
doi: 10.1371/journal.pone.0078313.t001
Figure 2.  Time-to-Hypothyroidism following initiation of MDR-TB treatment using Kaplan-Meier analysis.  
doi: 10.1371/journal.pone.0078313.g002
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found in this study suggests the need for routine screening for
hypothyroidism in HIV/DR-TB co-infected patients taking
ethionamide and/or PAS. This is currently not the case in India
and other resource-limited settings, where protocols
recommend measurement of TSH only if clinically indicated,
and not as part of routine monitoring[36]. WHO guidelines for
programmatic management of drug-resistant tuberculosis
recommend TSH monitoring at least every 6 months while
other guidelines advise screening every three months[2,4]. We
suggest TSH screening be done at baseline, at three months,
at six months, and every six months thereafter for HIV-infected
patients on MDR-TB treatment regimens containing PAS
and/or ethionamide, based on our findings that most of the
patients developed hypothyroidism within 90 days.
TSH testing can be challenging in resource-limited settings
due to limited availability. In Sewri TB hospital, a public facility,
patients with MDR-TB have no access to TSH testing unless
symptomatic (and often at a fee). A point-of-care (POC)
diagnostic tool for TSH screening would certainly be useful in
such settings. One such tool, TSH-CHECK-1, has shown
promising results as a screening test[38]; however,
confirmatory TSH testing would still be necessary following any
positive TSH-CHECK-1 result, since this rapid test does not
have sufficient specificity.
Ongoing efforts to find a better, more efficacious and less
toxic second-line TB regimen requiring considerably shorter
treatment duration should be the priority of the TB community.
Until that happens, we need to reduce as much as possible the
frequency of serious adverse events in MDR-TB patients with
or without HIV co-infection by systematically screening to
detect any adverse events early, including hypothyroidism.
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